: iStockAnalyst.com Symbols Feed

Stocks Turn Lower Ahead Of Earnings This Week

Mon, 13 Apr 2009 20:28:09 GMT

Stocks are trading lower today as investors prepare for key company earnings later in the week and brace for a potential bankruptcy filing from General Motors. At 12:36 pm ET, the Russell 2000 (NYSE:IWM) is down 7.71, or 1.65%, at 460.49. The Dow is down 0.92% and the S&P 500 is down 0.46%. Key banks, which kicked off a rally in early March when several institutions said they were profitable in the first two months of the year, will report quarterly earnings this week. Asian markets also gained more ground Monday as Japan's new $150 billion stimulus plan and upbeat news about Chinese bank lending boosted hopes for recovery in the region's major economies. Small caps on the rise this afternoon include AgFeed Industries (Nasdaq:[More...]

Beyond Stem Cells: Healthcare Hot Spots

Mon, 26 Jan 2009 18:09:00 GMT

With the surprise announcement last week by Geron (GERN) that the FDA would allow human clinical trials for embryonic stem cells, all companies in the underlying ETF Innovators Index to track the space are screaming higher again today – led by the company with the biggest gains over the past year, StemCells (STEM). Below are three additional areas and associated companies for investors to consider in the search of the next hot spots in the healthcare sector, including a focus on small/mid-cap companies which have the added potential to be acquired as part of renewed M&A in the sector this year. Molecular Diagnostics EXACT Sciences (EXAS) has rejected the hostile $1.50 all-stock offer from[More...]

Rigel Pharmaceuticals– Crisis Or Opportunity?

Mon, 10 Nov 2008 13:52:00 GMT

The past two weeks were anything but easy for Rigel’s (RIGL) shareholders, who saw their shares crash more than 50%. Rigel started 2008 on the right foot after a 200% jump in a single day last December, following impressive data for the company’s flagship[More...]

When There Is Blood In The Streets - Buy Biotech

Fri, 10 Oct 2008 23:32:00 GMT

History has shown again and again that times like these represent a huge long term buying opportunity. This may be particularly true for the biotech segment that, despite weathering the storm better than other segments, has had its share of price declines. During the past several weeks, great biotech stocks, from small early stage companies to fully commercialized companies have been thrown out of portfolios like bad auction rate securities, but the truth is that the value proposition of most of these biotechs did not change at all, and is not likely to change as a result of market conditions. This is why current prices create the best opportunity to get into the[More...]

Investing in microRNA - Beware of Hype, Follow The Money

Wed, 04 Jun 2008 17:19:04 GMT

The momentum in the microRNA (miRNA) field is continuing to build, as evidence that links this group of important genes to multiple diseases, from Alzheimer to diabetes, is constantly mounting. The adoption of miRNAs is further accelerated by the technological advancements in RNA-based therapies. Because miRNAs are not expressed as proteins but as RNA, the most sensible way to target them is using small RNA...[More...]

Rosetta Genomics - Mining Gold Out of Junk

Fri, 11 Apr 2008 06:05:15 GMT

Rosetta Genomics (ROSG) represents one of the most exciting revolutions in biology in recent decades. The company is a pioneer in the field of microRNAs (miRNAs), a group of recently discovered genes that may serve as a novel class of diagnostic markers[More...]

Rosetta Genomics - Mining Gold Out of Junk (Part I)

Thu, 24 Jan 2008 13:12:02 GMT

Rosetta Genomics - Mining Gold Out of Junk (Part I) Rosetta Genomics (ROSG) represents one of the most exciting revolutions in biology in recent decades. The company is a pioneer in the field of microRNAs (miRNAs), a group of recently discovered genes that may serve as a novel class of markers and drug targets. Unlike “traditional” genes we were familiar with, miRNA genes are not expressed as proteins, but as small RNA fragments that regulate the expression of many proteins. Rosetta Genomics’ impressive pipeline, unparalleled disco[More...]

Rosetta Genomics Reports Second Quarter Financial Results, Provides Business Update

Tue, 08 Sep 2009 20:49:00 GMT

Selling Parkway Clinical Laboratories for up to $2.5 million
"Building on distribution agreements covering the U.S., Israel and Turkey, we continued to build commercial momentum by signing three additional agreements for our first microRNA tests, which diagnose cancer metastases and differentiate between two types of lung cancer," said Amir Avniel, chief executive officer of Rosetta Genomics.
"Through an agreement with Warnex Medical Laboratories our products are now available in Canada; through an agreement with Super Religare Laboratories we added India and other countries; and through an agreement with AXA Diagnostics we added Italy, marking our entrÃ©e into Europe.

[More...]

Rosetta Genomics and Warnex Medical Laboratories Announce Exclusive Distribution Agreement for Rosetta’s microRNA-based Assays in Canada

Mon, 10 Aug 2009 11:29:00 GMT

Rosetta Genomics, Ltd. (NASDQ:ROSG), the leading developer of microRNA-based molecular diagnostics, and Warnex Medical Laboratories, a division of Warnex Inc. (TSX:WNX), announced today they have signed an exclusive distribution agreement in Canada for three currently-available diagnostic tests. Under the terms of the agreement, Warnex will market Rosetta Genomics’ miRview™ tests. Samples will be sent from Canada to Rosetta Genomics’ Philadelphia-based CLIA-certified laboratory for analysis. The terms of the deal were not disclosed.[More...]

Rosetta Genomics Passes California, Rhode Island, and Maryland CLIA Certification; Files 2008 Audited Financial Statements on Form 6-K

Wed, 17 Jun 2009 11:26:00 GMT

Rosetta Genomics, Ltd. (NASDAQ:ROSG) an innovative molecular diagnostic company leveraging microRNAs as biomarkers, today announced that its Philadelphia-based laboratory has passed the survey for CLIA (Clinical Laboratory Improvement Amendments) certification in California, Rhode Island and Maryland. This brings the number of states permitting commercial molecular diagnostics tests at Rosetta Laboratories to 48. Rosetta also announces that on June 11th it filed its audited financial statements with the U.S. Securities and Exchange Commission on Form 6-K. The financial statements provide additional information with respect to the terms of the license and collaboration agreement with Prometheus Laboratories, including the potential for Rosetta to receive up to $17 million in research and development, milestone and other payments in addition to royalties on the sale of the tests.[More...]

Rosetta Genomics To Present At The Eighth Annual Needham and Company Biotechnology and Medical Technology Conference

Mon, 08 Jun 2009 15:43:00 GMT

Rosetta Genomics, Ltd. (NASDAQ: ROSG), an innovative molecular diagnostic company leveraging microRNAs as biomarkers, announced that Amir Avniel, president and chief executive officer, will be presenting a corporate update at the Eighth Annual Needham and Company Biotechnology and Medical Technology Conference on Wednesday, June 10, 2009 at 8:30 a.m., (Eastern Daylight Time) at the New York Palace Hotel in New York City.[More...]

Rosetta Genomics Reports First Quarter Financial Results, Announces Sale of Parkway Clinical Laboratories

Thu, 21 May 2009 11:52:00 GMT

Making progress in developing our colon cancer screening test
"The first quarter of 2009 was a highly productive period for Rosetta Genomics, in particular because various actions we took are allowing us to turn our attention almost exclusively to the development of a colon cancer screening test," said Amir Avniel, president and chief executive officer of Rosetta Genomics.
"We were very pleased to give an oral presentation at this year's American Academy of Cancer Research on the feasibility of a serum-based microRNA colon cancer screen.

[More...]

Rosetta Genomics Announces Upcoming Scientific Presentations, Posters, and New Publication

Wed, 20 May 2009 12:02:00 GMT

Rosetta Genomics (NASDAQ:ROSG) today announced the company’s upcoming speaking events at the industry’s leading conferences.[More...]

Rosetta Genomics to Hold First Quarter Conference Call on May 21

Tue, 12 May 2009 11:00:00 GMT

Rosetta Genomics (NASDAQ: ROSG) today announced it will release financial results for the first quarter of 2009 on May 21, 2009 before the opening of NASDAQ trading, and will host a conference call and webcast to discuss those results and answer questions beginning at 10:30 a.m. Eastern time that same day.[More...]

Rosetta Genomics Announces Closing of License and Collaboration Agreement

Thu, 30 Apr 2009 12:10:00 GMT

Rosetta Genomics Ltd. (Nasdaq:ROSG), an innovative molecular diagnostic company, today announced the closing of its previously announced license and collaboration transaction with Prometheus Laboratories Inc., pursuant to which Rosetta has granted Prometheus U.S. rights to three recently introduced, microRNA-based cancer diagnostic tests: miRview™ mets, miRview™ squamous and miRview™ meso. In conjunction with the closing of the licensing transaction, the parties also closed the previously announced purchase of 2,000,000 Rosetta ordinary shares by Prometheus at $4.00 per share.[More...]

Rosetta Genomics to Give Oral Presentation on Colon Cancer Screening Diagnostic at AACR Annual Meeting

Mon, 20 Apr 2009 10:57:00 GMT

Rosetta Genomics, Ltd. (NASDAQ:ROSG), an innovative molecular diagnostic company leveraging microRNAs as biomarkers, reports that at the annual meeting of the American Association of Cancer Research it will present data on its lead product candidate, a noninvasive diagnostic being developed for colon cancer screening. The oral presentation, titled “Circulating microRNAs as potential blood-based biomarkers for diagnosis of colorectal cancer” will be given in a session on Biomarkers for Diagnosis, Prognosis, and Therapy Response on Tuesday, April 21, 2009, beginning at 10:00 a.m. local time. The meeting is being held April 18 – 22 in Denver at the Colorado Convention Center.[More...]

Prometheus and Rosetta Genomics Announce License and Collaboration Agreement

Mon, 13 Apr 2009 10:56:00 GMT

MicroRNA-based Molecular Diagnostics to Mark Prometheus' Entry into Oncology Market; Rosetta to Receive Milestones and Research and Development Funding plus Future Royalties[More...]